Why the study?
Myocarditis incidence increased after SARS-CoV-2 infection and mRNA vaccination, yet diagnosis remains challenging, and emerging genetic and molecular mechanisms behind disease heterogeneity and long-term risk require synthesis.
This review highlights the integration of clinical, molecular, and genetic perspectives to understand COVID-19-associated myocarditis, emphasizing the need for personalized risk stratification and post-recovery surveillance.
Answers are grounded in this paper and cite their sources.
Supports genetic role in COVID-19 myocarditis severity; leaves open personalized stratification pending prospective validation.
Myocarditis is a non-familial inflammatory manifestation of the myocardium, primarily induced by viral infections, but it may also stem from bacterial pathogens, autoimmune disorders, or adverse drug reactions. Its diagnosis remains challenging due to heterogeneous and often non-specific clinical presentations. Recent epidemiological studies have indicated a markedly increased incidence of myocarditis following SARS-CoV-2 infection and mRNA COVID-19 vaccinations (to a lesser extent) compared to pre-pandemic statistics. While a significant number of cases follow a mild and self-limiting disease course, severe manifestations can lead to arrhythmias, heart failure, or even sudden cardiac death. Importantly, accumulating evidence indicates that even mild myocarditis confers an elevated long-term risk of adverse cardiovascular outcomes. Beyond clinical and imaging-based observations, recent advances highlight a critical role for host genetic susceptibility in modulating immune responses, myocardial injury, and disease severity. This review provides a comprehensive synthesis of the etiology, pathophysiological mechanisms, clinical spectrum, diagnostic approaches, and evidence-based management of COVID-19-associated myocarditis, while critically integrating emerging genetic and transcriptomic insights that may explain disease heterogeneity, variable inter-individual susceptibility, and long-term prognosis. By bridging clinical aspects with molecular and genetic frameworks, this review underscores the importance of personalized risk stratification, vigilant post-recovery surveillance, and targeted preventive strategies in the post-pandemic era.
No takes yet. Share an insight, caveat, or question.
Birla et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: